



PolyNovo Limited
ABN 96 083 866 862

2/320 Lorimer Street
Port Melbourne
VIC Australia 3207

P +61 (0) 3 8681 4050
F +61 (0) 3 8681 4099

7 March 2025

ASX Announcement

Response to article in 'Margin Call'

PolyNovo Limited (ASX: PNV) refers to the article in this morning's 'Margin Call' column in The Australian newspaper.

PNV confirms that on Friday last week there was a confidential discussion with the Chief Executive Officer, Mr Swami Raote, requesting his agreement to cease his employment with PNV effective June 2025 at the end of his contractual notice period and to step down as Chief Executive Officer effective from an earlier date. The discussion proposed terms for his separation if agreement was reached and revealed that non-executive director, Dr Robyn Elliott, would be stepping into the role as Acting Chief Executive Officer pending the appointment of a permanent replacement.

This announcement has been authorised by the Board of PolyNovo Limited.

[About PolyNovo®](#)

PolyNovo is a disruptive ASX 200 medical technology company, based out of Melbourne, Australia. Its products simplify management of acute complex wounds, redefining healing with meaningfully differentiated patient outcomes across multiple wound etiologies. After treating 50,000+ patients across 41 countries, the company is investing for growth via new products, indications, and markets. For more information see polynovo.com.

[About NovoSorb®](#)

NovoSorb BTM is a dermal scaffold for the regeneration of the dermis when lost through extensive surgery, trauma or burn. NovoSorb is a novel range of bio-resorbable polymers that can be produced in many formats including film, fibre, foam, and coatings. NovoSorb's unique properties provide excellent biocompatibility, control over physical properties, and a programmable bio-resorption profile.

Further information:

Lior Harel
General Counsel & Company Secretary
1800 958 289 / investor@polynovo.com